Annual Report 2011 - Center for Advanced Biotechnology and ...

More documents

Recommendations

Info

Laboratory Faculty Director Structural Biology Protein Engineering Stephen Anderson 40 Biomolecular Crystallography Edward Arnold 42 Structural Biology and Bioinformatics Helen Berman 47 Structural Microbiology Joseph Marcotrigiano 51 Structural Bioinformatics Gaetano Montelione 54 Protein Design and Evolution Vikas Nanda 62 Protein Crystallography Ann Stock 65 39
Dr. Stephen Anderson CABM Resident Faculty Member Associate Professor Department of Molecular Biology and Biochemistry Rutgers University Yi-Wen Chiang Lab Researcher Protein Engineering Laboratory Dr. Stephen Anderson conducted his postdoctoral research under Nobel laureate Dr. Frederick Sanger at the MRC Laboratory of Molecular Biology in Cambridge, England. That project involved the sequencing of human and bovine mitochondrial genomes. He went on to a position at the Californiabased biotechnology start-up company Genentech. Anderson has held research or teaching positions at Harvard University, the MRC Laboratory of Molecular Biology, Genentech, Inc., University of California, San Francisco, and Rutgers University. While at Genentech he was responsible for all specialty chemical projects and second generation tissue plasminogen activator research. In 2011 the lab embarked on a three-year $2.8M NIH-funded project to express a representative set of antigens derived from human transcription factors. The collaborators and co-PIs on this project are Profs. Gaetano T. Montelione and Joseph Marcotrigiano, both of CABM and Rutgers, and Prof. Cheryl Arrowsmith of the Ontario Cancer Research Center and the University of Toronto. Late in 2011, NIH identified two “affinity capture reagent” consortia for our antigen production group to partner with: one, headed by Prof. Anthony Kossiakoff at the University of Chicago and including groups at UCSF and University of Toronto, that will be making Fabs and antibodies using high throughput phage display technology; and one based at Johns Hopkins University, headed by Prof. Jef Boike, that has invented a low-cost, high throughput method of isolating and screening traditional monoclonal antibodies. NIH’s overarching goal is to eventually produce renewable cognate affinity capture reagents (including antibodies) directed against every human protein, an effort that has been unofficially dubbed the “Human Anti-Proteome Project”. NIH wants to make such reagents available to the research community as powerful tools for studying human biology. A description of this initiative is at http://commonfund.nih.gov/proteincapture/index.aspx. The effort that we are undertaking, namely producing human transcription factor antigens for affinity capture reagent production, is a pilot project designed to kick-start this overall effort. The first envisioned application for the anti-TF antibodies is to enable chromatin immunoprecipitation (ChIP) studies aimed at obtaining a complete map of potential transcription start sites in the human genome – much of this work is being carried out by the NIH-funded ENCODE Consortium. 40
Page 1: CENTER FOR ADVANCED BIOTECHNOLOGY A
Page 4 and 5: Director’s Overview CABM—25 and
Page 6 and 7: of Health, National Science Foundat
Page 8 and 9: Cell & Developmental Biology Labora
Page 10 and 11: protein metabolism/activity, such t
Page 12 and 13: Dr. Céline Gélinas CABM Resident
Page 14 and 15: (CHINJ, CINJ and CABM) and Lauri Go
Page 16 and 17: Dr. Masayori Inouye CABM Resident F
Page 18 and 19: Xu, Z., Mirochnitchenko, O., Xu, C.
Page 20 and 21: Dr. Fang Liu CABM Resident Faculty
Page 22 and 23: Publications: Matsuura, I., Chiang,
Page 24 and 25: In the prior year, we have made con
Page 26 and 27: Dr. James Millonig CABM Resident Fa
Page 28 and 29: We have mapped 5 different vl modif
Page 30 and 31: Dr. Arnold Rabson Director Child He
Page 32 and 33: Publications: Zheng, X., Cui, X.X.,
Page 34 and 35: polymerase II, facilitating the sel
Page 36 and 37: Dr. Mengqing Xiang CABM Resident Fa
Page 38 and 39: neurons diminish while there is a s
Page 42 and 43: Human transcription factors are typ
Page 44 and 45: atomic detail and have yielded nume
Page 46 and 47: Figure from Das et al., 2011 showin
Page 48 and 49: Dr. Helen M. Berman Board of Govern
Page 50 and 51: Dr. Chenghua Shao Research Associat
Page 52 and 53: Dr. Joseph Marcotrigiano CABM Resid
Page 54 and 55: The long-term goals of our studies
Page 56 and 57: s Publications: Singarapu, K.K., Mi
Page 58 and 59: Zhao, L., Zhao, K., Hurst, R., Slat
Page 60 and 61: Acton, T.B., Xiao, R., Anderson, S.
Page 62 and 63: Kryshtafovych, A., Bartual, S.G., B
Page 64 and 65: properties by lowering susceptibili
Page 66 and 67: Dr. Ann M. Stock Associate Director
Page 68 and 69: Publications: Barbieri, C.M., Mack,
Page 70 and 71: Lectures and Seminars 69
Page 72 and 73: CABM RETREAT, June 30, 2011 Cook Ca
Page 75 and 76: 25 th Anniversary CABM Symposium Fr
Page 77 and 78: Edery Lab Joseph Albistur George Gh
Page 79 and 80: PATENTS P. Lobel, et al. “Methods
Page 81 and 82: Montelione, G.T., Ma, L. and Krug,
Page 83 and 84: Outside Academic Members Dr. Wayne
Page 85 and 86: Former CABM Scientific Advisory Boa
Page 87 and 88: Fiscal Information 86
Page 89 and 90: Anderson, Stephen Rutgers CABM Gran
Page 91 and 92:
Leukemia & Lymphoma Society BFL-1 a
Page 93 and 94:
Total Award Start - End FY 2011 Dir
Page 95 and 96:
Department of Defense Tumor suppres
Page 97 and 98:
Total Award Start - End FY 2011 Dir
show all

Annual Report 2011 - Center for Advanced Biotechnology and ...

Create successful ePaper yourself

Delete template?

Save as template?